Bulk St. John’s Wort Extract Supplier — Hyperforin 1%–3%, Hypericin 0.3%–0.9%, B2B Wholesale
Valeherb supplies St. John’s Wort extract bulk wholesale — Hypericum perforatum L. flowering tops extract — standardized to hyperforin 1%–3%, total hypericin 0.3%–0.9%, and hyperoside 1%–1.5%, all by HPLC (total hypericin also available by UV). Derived from the dried flowering tops harvested at or shortly before flowering, this is one of the most extensively studied botanical extracts in published clinical and pharmacological research, with a well-characterised compound profile spanning naphthodianthrones (hypericin), phloroglucinols (hyperforin), and flavonoids (hyperoside).
On this page: available grades, active compound profile, research background, formulation applications, sourcing criteria, and regulatory guidance.
Available Grades
| Compound | Content Range | Assay Method |
|---|---|---|
| Hyperforin | 1%–3% | HPLC |
| Total Hypericin | 0.3%–0.9% | HPLC / UV |
| Hyperoside | 1%–1.5% | HPLC |
Custom compound ratios and single-marker standardization available on request. MOQ, lead time, and current pricing available on inquiry.
Active Compound Profile
| Compound | Class | Notes |
|---|---|---|
| Hyperforin | Phloroglucinol derivative | Lipophilic; light- and heat-sensitive; the primary driver of the extract’s documented enzyme-induction activity — interaction risk correlates directly with hyperforin content[1] |
| Hypericin & Pseudohypericin | Naphthodianthrones | Red pigment compounds; photosensitising; the standard marker compounds referenced in ChP and EP monographs |
| Hyperoside | Flavonol glycoside | Contributes to the extract’s broader flavonoid profile alongside quercetin, rutin, and isoquercitrin |
Research Background
Provided as scientific context for formulators, not as claims for any Valeherb product.
Mechanism and Enzyme Induction
Hyperforin has been identified in published research as a potent activator of the pregnane X receptor (PXR), which upregulates expression of cytochrome P450 enzymes — particularly CYP3A4 — and the P-glycoprotein transporter. This mechanism is well-characterised and is the basis for the extract’s documented herb-drug interaction profile discussed in the Caution section below.[1],[2]
Central Nervous System Research
Published preclinical research has investigated multiple proposed mechanisms for Hypericum perforatum‘s activity in central nervous system models, including hyperforin’s studied effects on synaptosomal reuptake of several neurotransmitters, hypericin’s studied MAO-A/B inhibitory activity, and flavonoid-mediated GABA receptor modulation.[4] These are preclinical mechanistic findings described here as research context; Hypericum perforatum-containing products intended for mood-related use are regulated as herbal medicinal products or drugs in most major markets and require separate regulatory pathways from dietary supplement or cosmetic ingredient positioning.
Formulation Applications
- Herbal medicinal products (EU / regulated markets): Standardized extracts are formulated into licensed herbal medicinal products under EU HMPC monograph requirements, typically as low-hyperforin preparations to manage interaction risk
- TCM and traditional herbal formulations: Full-spectrum flowering tops extract in traditional formula blends; ChP documentation available for China domestic market and TCM-positioned export products
- Topical and cosmeceutical applications: Oil macerate and extract-based topical formulations have documented traditional use for skin applications; photosensitising activity of hypericin must be disclosed and accounted for in formulation and labelling
- Research applications: Standardized extract and individually quantified marker compounds (hyperforin, hypericin, hyperoside) for pharmacological and analytical research
Sourcing Criteria
| Criterion | What to Require |
|---|---|
| Plant Part & Harvest Stage | Flowering tops (aerial parts harvested at or shortly before flowering) confirmed on COA — per European Pharmacopoeia and ChP standards. Confirm this is not stem- or leaf-only material, which has a different compound profile |
| Hyperforin Content | HPLC-verified hyperforin content per batch — the key specification for interaction-risk assessment and regulatory positioning |
| Hypericin Content | Total hypericin (hypericin + pseudohypericin) by HPLC or UV per batch, matched to the ChP/EP standard marker range |
| Third-Party COA | Hyperforin, total hypericin, hyperoside (HPLC), heavy metals, pesticide residues, microbial limits, moisture — per production batch from accredited laboratory |
Regulatory Guidance
- EU: Hypericum perforatum preparations are recognised under HMPC monographs as herbal medicinal products (traditional use or well-established use registration), requiring mandatory interaction warnings on labelling. Not positioned as a standard food supplement ingredient without appropriate registration
- US (DSHEA): Marketed as a dietary supplement ingredient; not FDA-approved as a drug. FDA and other regulatory bodies have issued public communications regarding CYP3A4-mediated drug interactions — finished-product labelling should reflect current interaction warning guidance
- China (ChP): Listed in the Chinese Pharmacopoeia with defined hypericin and hyperforin marker specifications; ChP compliance documentation available for domestic China market and export
- General: Given the extensive documented interaction profile, Valeherb recommends that finished-product formulators consult current regulatory and pharmacovigilance guidance for their specific target market and intended use before formulation
